Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy

J Urol. 1996 Apr;155(4):1296-8.

Abstract

Purpose: We assessed the efficacy of primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and elevated serum tumor markers as the only evidence of disease after orchiectomy.

Materials and methods: We analyzed the outcome of 20 patients with biological disease only who received cisplatin-based (16) or carboplatin-based (4) chemotherapy as primary treatment following orchiectomy.

Results: Serum tumor markers returned to normal levels in all 20 patients. One patient required subsequent surgery for recurrent retroperitoneal mature teratoma. Two patients experienced a relapse with active disease, 1 of whom died of progressive germ cell tumor. Of the patients 19 remained free of disease 18 to 116 months after the end of treatment.

Conclusions: Since results with primary retroperitoneal lymph node dissection suggest that elevated serum tumor markers usually reflect systemic metastases rather than retroperitoneal disease, primary chemotherapy seems to be the most appropriate strategy to consider in patients with biological disease only following orchiectomy.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood
  • Carboplatin / administration & dosage
  • Chorionic Gonadotropin / blood
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Disease-Free Survival
  • Germinoma / drug therapy*
  • Germinoma / mortality
  • Germinoma / surgery
  • Humans
  • Male
  • Orchiectomy*
  • Testicular Neoplasms / drug therapy*
  • Testicular Neoplasms / mortality
  • Testicular Neoplasms / surgery
  • Treatment Outcome
  • alpha-Fetoproteins / analysis

Substances

  • Biomarkers, Tumor
  • Chorionic Gonadotropin
  • alpha-Fetoproteins
  • Carboplatin
  • Cisplatin